MLchartDataset catalogue

Telotristat etiprate

Term · Oncology and biomedicine · MLC-T-ONC-017057

An orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor prodrug, with potential antiserotonergic activity. Upon administration, telotristat etiprate is converted to its active moiety, telotristat (LP-778902), which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.

Table 1. Record
IdentifierMLC-T-ONC-017057
FieldOncology and biomedicine
Synonymstelotristat ethyl; tryptophan hydroxylase inhibitor LX1032; TPH inhibitor LX1606; TPHI inhibitor LX1032
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017057",
  "term": "Telotristat etiprate",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor prodrug, with potential antiserotonergic activity. Upon administration, telotristat etiprate is converted to its active moiety, telotristat (LP-778902), which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.",
  "synonyms": [
    "telotristat ethyl",
    "tryptophan hydroxylase inhibitor LX1032",
    "TPH inhibitor LX1606",
    "TPHI inhibitor LX1032"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/telotristat-etiprate/"
}

Record 16,125 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.